Abivax Highlights Obefazimod Ulcerative Colitis Program With New Data to be Presented at the UEG Week 2023

Oral presentation of Phase 2b, 96-week, open-label, maintenance efficacy and safety in obefazimod-treated patients with moderately to severely active ulcerative colitis (UC)Moderated poster presentation highlighting correlation of pharmacokinetic …